Publicaciones en las que colabora con Vicente Estrada Pérez (14)

2022

  1. Does admission acetylsalicylic acid uptake in hospitalized COVID-19 patients have a protective role? Data from the Spanish SEMI-COVID-19 Registry

    Internal and Emergency Medicine, Vol. 17, Núm. 3, pp. 761-775

2021

  1. Evolution of the use of corticosteroids for the treatment of hospitalised COVID-19 patients in Spain between March and November 2020: SEMI-COVID national registry

    Journal of Clinical Medicine, Vol. 10, Núm. 19

2018

  1. Increased indoleamine-2,3-dioxygenase activity is associated with poor clinical outcome in adults hospitalized with influenza in the INSIGHT FLU003Plus study

    Open Forum Infectious Diseases, Vol. 5, Núm. 1

2016

  1. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013

    Journal of Infection, Vol. 72, Núm. 5, pp. 587-596

2015

  1. Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection: A case control study

    PLoS ONE, Vol. 10, Núm. 10

  2. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

    PLoS Medicine, Vol. 12, Núm. 3

2014

  1. Diagnosis of subclinical atherosclerosis in HIV-infected patients: Higher accuracy of the D:A:D risk equation over Framingham and SCORE algorithms

    European Journal of Preventive Cardiology, Vol. 21, Núm. 6, pp. 739-748

2012

  1. Cardiovascular disease risk in HIV infection and endothelial progenitor cells

    Journal of Infectious Diseases

  2. Endothelial dysfunction in HIV infection - The role of circulating endothelial cells, microparticles, endothelial progenitor cells and macrophages

    AIDS Reviews, Vol. 14, Núm. 4, pp. 223-230

2009

  1. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): A randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance

    Journal of Antimicrobial Chemotherapy, Vol. 64, Núm. 2, pp. 398-410

2007

  1. Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV infection: The ELADI study

    AIDS Research and Human Retroviruses, Vol. 23, Núm. 10, pp. 1237-1241

2005

  1. Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: Final results of the EFADITE trial

    Antiviral Therapy, Vol. 10, Núm. 7, pp. 825-832

2003

  1. Role of baseline human immunodeficiency virus genotype as a predictor of viral response to tenofovir in heavily pretreated patients

    Journal of Clinical Microbiology, Vol. 41, Núm. 9, pp. 4421-4423

2000

  1. Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids

    AIDS, Vol. 14, Núm. 14, pp. 2153-2157